Zacks: Brokerages Anticipate Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Will Announce Earnings of $0.27 Per Share

Equities research analysts forecast that Supernus Pharmaceuticals, Inc. (NASDAQ:SUPNGet Rating) will announce earnings per share (EPS) of $0.27 for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Supernus Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at $0.17 and the highest estimate coming in at $0.36. Supernus Pharmaceuticals posted earnings of $0.11 per share in the same quarter last year, which indicates a positive year-over-year growth rate of 145.5%. The firm is expected to issue its next earnings results on Monday, January 1st.

On average, analysts expect that Supernus Pharmaceuticals will report full-year earnings of $1.58 per share for the current year, with EPS estimates ranging from $1.37 to $1.80. For the next financial year, analysts anticipate that the company will post earnings of $0.97 per share, with EPS estimates ranging from $0.25 to $1.44. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that that provide coverage for Supernus Pharmaceuticals.

Supernus Pharmaceuticals (NASDAQ:SUPNGet Rating) last announced its quarterly earnings data on Wednesday, April 13th. The specialty pharmaceutical company reported $0.04 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.25). Supernus Pharmaceuticals had a net margin of 14.49% and a return on equity of 10.56%.

Several research firms have commented on SUPN. assumed coverage on shares of Supernus Pharmaceuticals in a report on Thursday, March 31st. They issued a “hold” rating on the stock. Zacks Investment Research downgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, March 4th.

NASDAQ:SUPN opened at $31.10 on Friday. Supernus Pharmaceuticals has a one year low of $23.15 and a one year high of $34.50. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.59 and a current ratio of 2.85. The firm has a market cap of $1.64 billion, a price-to-earnings ratio of 31.73 and a beta of 1.10. The firm’s fifty day moving average is $31.48 and its two-hundred day moving average is $30.68.

A number of hedge funds have recently modified their holdings of the business. UMB Bank N A MO acquired a new stake in shares of Supernus Pharmaceuticals in the 4th quarter valued at $29,000. Eagle Bay Advisors LLC increased its stake in Supernus Pharmaceuticals by 70.9% in the fourth quarter. Eagle Bay Advisors LLC now owns 1,444 shares of the specialty pharmaceutical company’s stock valued at $42,000 after purchasing an additional 599 shares during the period. C M Bidwell & Associates Ltd. acquired a new position in Supernus Pharmaceuticals in the fourth quarter valued at $43,000. First Horizon Advisors Inc. increased its stake in Supernus Pharmaceuticals by 1,275.9% in the fourth quarter. First Horizon Advisors Inc. now owns 1,486 shares of the specialty pharmaceutical company’s stock valued at $43,000 after purchasing an additional 1,378 shares during the period. Finally, Banque Cantonale Vaudoise boosted its holdings in shares of Supernus Pharmaceuticals by 64.4% in the third quarter. Banque Cantonale Vaudoise now owns 1,787 shares of the specialty pharmaceutical company’s stock valued at $48,000 after acquiring an additional 700 shares in the last quarter.

Supernus Pharmaceuticals Company Profile (Get Rating)

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its commercial products include Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.

Featured Stories

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with's FREE daily email newsletter.